Skip to content

Evaluation of Different Protein Content of Formulas on Nutrition Status of Infants.

Evaluation of the Impact of Infant Formulas With Different Protein Content on Growth, Gastrointestinal Tolerance, and B-casomorphin Concentration of Infants.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03513991
Enrollment
20
Registered
2018-05-02
Start date
2016-02-15
Completion date
2017-08-08
Last updated
2018-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding of Healthy Full Term Infants, Formula Feeding of Healthy Full Term Infants, Growth & Development

Keywords

human milk, infant formula with low protein, alpha lactoalbumin, growth velocity, gastrointestinal events

Brief summary

Human milk (HM) is the gold standard of early infant nutrition. The World Health Organization (WHO) recommend that newborns be exclusively breastfed for the first 6 months of life. It has beed reported that an exclusive breast feeding at 6 months of age range from 10 to 46%. Thus, the intake of infant formulas (IF) is quite widespread, including infants that have less than 6 months that are not receiving breast milk. Most of the commercial IF are cow's milk-based formulas that have a higher concentration of protein than breast milk and have a different protein composition. Commercial IF have a low proportion of alpha lactoalbumin, and A1 β-casein; during its digestion, a β-casomorphin 7 peptide is produced. In addition, it has a high concentration of β-lactoglobulin. Both, β-casomorphin 7 and β-lactoglobulin have been associated with a higher risk of diabetes obesity and allergies. Human β-casein does not produce β-casomorphin 7 during its digestion, it has a high concentration of alpha-lactoalbumin and does not have β-lactoglobulin. The purpose of this study is to evaluate growth, gastrointestinal tolerance, and β-casomorphin 7 in urine of infants that are exclusively breastfed compared to infants fed three IF with different proteint content.

Detailed description

Developing an IF with A2 β-casein, high proportion of alpha-lactoalbumin and less protein that commercial IF, similar to breast milk (1g/100 mL), could be and important strategy to decrease the risk of diseases. This infant formula was compared with breast milk and two other IF with different protein composition. The three formulas were packed in the same presentation and identified by a number. Mothers voluntarily elected to exclusively breast-feed or formula-feed her newborn. the present study Infants' mothers were recruited from six health centers from the Health Ministry in Querétaro, México. Directors of each health center authorized the protocol study. The field workers were read and explained the informed consent letter, the objectives, procedures, risks and benefits of the study in detail.

Interventions

OTHERInfant formula

Sponsors

NUCITEC S.A. de C.V.
CollaboratorUNKNOWN
Universidad Autonoma de Queretaro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

The participant did not know which formula was assigned. Infant formulas were packed in the same presentation and identified by a number.

Intervention model description

The exclusively formula-fed infants were randomized to one of three study formulas with different protein profile. A control group was selected with women that voluntarily chose to exclusively breast feed for at least 4 months.

Eligibility

Sex/Gender
ALL
Age
1 Days to 40 Days
Healthy volunteers
Yes

Inclusion criteria

* Full-term newborn (≥37 weeks of gestation) * Birth weight ≥2500 g and ≤4000 g * Apgar score \> 8 * Infants from birth to 40 days of age at the time of enrollment * Mothers voluntarily elected to exclusively breast-feed or formula-feed her newborn.

Exclusion criteria

* Infants with congenital heart defect, congenital illness or malformations, severe gastrointestinal disease, kidney, liver, central nervous system, or metabolic disease, or born from mothers with gestational diabetes.

Design outcomes

Primary

MeasureTime frameDescription
Change in weightBaseline to 4 months of ageWeight

Secondary

MeasureTime frameDescription
Anthropometry measurementsBaseline, 1, 2 ,3 and 4 months of ageMeasurements will include length and head circumference, and together with the primary outcome of weight, will be used to calculate z-scores using WHO Growth Standards.
Beta-casomorphin 7 concentrationBaseline and at 4 months of ageQuantification of beta-casomorphin 7 concentration in urine
Number of gastrointestinal eventsBaseline, 1, 2, 3, and 4 monthsGastrointestinal events will be recorded by the mothers. These events include: constipation, diarrhea, regurgitation, vomit, reflux, colic, constant crying, and stool consistency and color, using previously reported scales (Bekkali et al, 2009; Trabulsi, 2011).

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026